Build a reference frame, save a practice trade, or preview a draft. No brokerage order is placed.
Paper trade unavailable: missing risk-bounded frame
Reference only. Not financial advice. No brokerage order is placed.
Why $NVS?
NVS-7WATCHbiotech
Quantitative
Convergence score: -7 (6 signals firing YoY)
Catalysts
Clinical trial milestone: Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.
Clinical trial milestone: A Study to Investigate the Pharmacokinetics and Safety of Remibrutinib in Participants With Hepatic Impairment Compared With Matched Healthy
Risks
Position-sizing discipline: Conviction WATCH (-7 score) — size accordingly; no specific catalyst-fade risk flagged
Bear case
Squeeze unwind: Short interest can compress before retail catches the move — entry timing critical
Tickers Catalyst Edge tracks as moving with this name. Cross-correlation derived from sector + score-cohort proximity.
Earnings Catalyst
No recent earnings event.
Auto-generated from public filings + tier-1 wires. Catalyst Edge publishes its picks and its losses — see the trust report and methodology.
Not financial advice. Confirm independently before trading.
You came here for NVS. You found it after it moved, the same way everyone else did.
$99 once — every ticker on this site ranked before the open.